HomeProductsBuilding BlocksHeterocyclic ScaffoldsOther Aromatic HeterocyclesAbivertinib
Chemical structure of CAS 1557267-42-1

Abivertinib

CAS No.1557267-42-1
MDL No.MFCD29089376
MFC26H26FN7O2
MW487.50
InChI KeyUOFYSRZSLXWIQB-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1557267-42-1
Product NameAbivertinib

Biological Targets

EGFR·BTK

Associated Conditions

neoplasm of mature B-cells·COVID-19·non-small cell lung carcinoma·prostate cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 28, Issue 6 • 2022
PMID: 34740925PMC: PMC9365372DOI: 10.1158/1078-0432.CCR-21-2595

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • Vol. 13, Issue 7 • 2018
PMID: 29626621DOI: 10.1016/j.jtho.2018.03.025

Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.

Journal of cancer research and clinical oncology • Vol. 144, Issue 4 • 2018
PMID: 29392403PMC: PMC11813394DOI: 10.1007/s00432-017-2570-8

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.

Molecular cancer therapeutics • Vol. 15, Issue 11 • 2016
PMID: 27573423DOI: 10.1158/1535-7163.MCT-16-0281

Documentation

Similar Products